2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

• Published in: Supportive care in cancer 2024-01, Vol.32 (1), p.37-37, Article 37
• Main Authors: Olver, Ian, Clark-Snow, Rebecca, Ruhlmann, Christina H., Garcia-del-Barrio, Maria-Angeles, Schwartzberg, Lee, Rapoport, Bernardo Leon, Jahn, Franziska
• Format: Article
• Language: English
• Subjects: Antiemetics; Antiemetics - therapeutic use; Antineoplastic Agents - adverse effects; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical practice guidelines; Consensus; Disease prevention; Emetics; Humans; Medical colleges; Medicine; Medicine & Public Health; Nausea; Nausea - chemically induced; Nausea - drug therapy; Nausea - prevention & control; Nursing; Nursing Research; Oncology; Pain Medicine; Palonosetron; Practice Guidelines as Topic; Rehabilitation Medicine; Side effects; Special Section; Systematic Reviews as Topic; Vomiting; Vomiting - chemically induced; Vomiting - drug therapy; Vomiting - prevention & control
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-023-08223-2

Purpose Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential. Methods A working group performed a systematic literature review using Medline, Embase, and Scopus databases between June 2015 and January 2023 of the management of antiemetic prophylaxis for anticancer therapy of low or minimal emetic potential. A consensus committee reviewed recommendations and required a consensus of 67% or greater and a change in outcome of at least 10%. Results Of 293 papers identified, 15 had information about managing systemic cancer treatment regimens of low or minimal emetic potential and/or compliance with previous management recommendations. No new evidence was reported that would change the current MASCC recommendations. No antiemetic prophylaxis is recommended for minimal emetic potential therapy, and single agents recommended for low emetic potential chemotherapy for acute emesis, but no prophylaxis is recommended for delayed emesis. Commonly, rescue medication includes antiemetics prescribed for the next higher level of emesis. Conclusion There is insufficient data to change the current guidelines. Future studies should seek to more accurately determine the risk of emesis with LEC beyond the emetogenicity of the chemotherapy to include patient-related risk assessment.